{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:01:22Z","timestamp":1785542482053,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-69123-x","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:05:25Z","timestamp":1723003525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging multisystem biomarkers in hereditary transthyretin amyloidosis: a pilot study"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7539-505X","authenticated-orcid":false,"given":"Marco","family":"Luigetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Ausilia","family":"Sciarrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Guglielmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelangelo","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sabino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serenella","family":"Servidei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geny","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Graziani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Lillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Primiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"69123_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams, D., Koike, H., Slama, M. & Coelho, T. Hereditary transthyretin amyloidosis: A model of medical progress for a fatal disease. Nat. Rev. Neurol. 15, 387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"69123_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli, F. et al. Hereditary transthyretin amyloidosis overview. Neurol. Sci. 43, 595\u2013604. https:\/\/doi.org\/10.1007\/s10072-020-04889-2 (2022).","journal-title":"Neurol. Sci."},{"key":"69123_CR3","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3390\/brainsci11080980","volume":"11","author":"PM Ferraro","year":"2021","unstructured":"Ferraro, P. M. et al. Renal involvement in hereditary transthyretin amyloidosis: An Italian single-centre experience. Brain Sci. 11, 980. https:\/\/doi.org\/10.3390\/brainsci11080980 (2021).","journal-title":"Brain Sci."},{"key":"69123_CR4","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/genes12060927","volume":"12","author":"AM Minnella","year":"2021","unstructured":"Minnella, A. M. et al. Ocular involvement in hereditary transthyretin amyloidosis: A case series describing novel potential biomarkers. Genes (Basel) 12, 927. https:\/\/doi.org\/10.3390\/genes12060927 (2021).","journal-title":"Genes (Basel)"},{"key":"69123_CR5","doi-asserted-by":"publisher","first-page":"339","DOI":"10.15403\/jgld-2474","volume":"29","author":"M Luigetti","year":"2020","unstructured":"Luigetti, M. et al. Gastrointestinal manifestations in hereditary transthyretin amyloidosis: A single-centre experience. J. Gastrointestin. Liver Dis. 29, 339\u2013343. https:\/\/doi.org\/10.15403\/jgld-2474 (2020).","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"69123_CR6","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/brainsci12121708","volume":"12","author":"M Luigetti","year":"2022","unstructured":"Luigetti, M. et al. Serum inflammatory profile in hereditary transthyretin amyloidosis: Mechanisms and possible therapeutic implications. Brain Sci. 12, 1708. https:\/\/doi.org\/10.3390\/brainsci12121708 (2022).","journal-title":"Brain Sci."},{"key":"69123_CR7","doi-asserted-by":"publisher","first-page":"16133","DOI":"10.3390\/ijms232416133","volume":"23","author":"M Luigetti","year":"2022","unstructured":"Luigetti, M. et al. A metabolic signature of hereditary transthyretin amyloidosis: A pilot study. Int. J. Mol. Sci. 23, 16133. https:\/\/doi.org\/10.3390\/ijms232416133 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"69123_CR8","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","volume":"17","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. GDF15: Emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat. Rev. Endocrinol. 17, 592\u2013607. https:\/\/doi.org\/10.1038\/s41574-021-00529-7 (2021).","journal-title":"Nat. Rev. Endocrinol."},{"key":"69123_CR9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2174\/1573403x12666160111125304","volume":"12","author":"M George","year":"2016","unstructured":"George, M., Jena, A., Srivatsan, V., Muthukumar, R. & Dhandapani, V. E. GDF 15\u2013a novel biomarker in the offing for heart failure. Curr. Cardiol. Rev. 12, 37\u201346. https:\/\/doi.org\/10.2174\/1573403x12666160111125304 (2016).","journal-title":"Curr. Cardiol. Rev."},{"key":"69123_CR10","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1373\/clinchem.2016.255174","volume":"63","author":"KC Wollert","year":"2017","unstructured":"Wollert, K. C., Kempf, T. & Wallentin, L. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clin. Chem. 63, 140\u2013151. https:\/\/doi.org\/10.1373\/clinchem.2016.255174 (2017).","journal-title":"Clin. Chem."},{"key":"69123_CR11","doi-asserted-by":"publisher","first-page":"12200","DOI":"10.1038\/s41598-019-48513-6","volume":"9","author":"D Kim","year":"2019","unstructured":"Kim, D. et al. Prognostic values of novel biomarkers in patients with AL amyloidosis. Sci. Rep. 9, 12200. https:\/\/doi.org\/10.1038\/s41598-019-48513-6 (2019).","journal-title":"Sci. Rep."},{"key":"69123_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/acn3.51104","volume":"7","author":"Y Lin","year":"2020","unstructured":"Lin, Y. et al. Accuracy of FGF-21 and GDF-15 for the diagnosis of mitochondrial disorders: A meta-analysis. Ann. Clin. Transl. Neurol. 7, 1204\u20131213. https:\/\/doi.org\/10.1002\/acn3.51104 (2020).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"69123_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/jpm12040548","volume":"12","author":"M Mizdrak","year":"2022","unstructured":"Mizdrak, M., Kumri\u0107, M., Kurir, T. T. & Bo\u017ei\u0107, J. Emerging biomarkers for early detection of chronic kidney disease. J. Pers. Med. 12, 548. https:\/\/doi.org\/10.3390\/jpm12040548 (2022).","journal-title":"J. Pers. Med."},{"key":"69123_CR14","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/HJH.0000000000001527","volume":"36","author":"A Leiherer","year":"2018","unstructured":"Leiherer, A. et al. The value of uromodulin as a new serum marker to predict decline in renal function. J. Hypertens. 36, 110\u2013118. https:\/\/doi.org\/10.1097\/HJH.0000000000001527 (2018).","journal-title":"J. Hypertens."},{"key":"69123_CR15","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1080\/13506129.2018.1545640","volume":"25","author":"M Luigetti","year":"2018","unstructured":"Luigetti, M. et al. Sudoscan in the evaluation and follow-up of patients and carriers with TTR mutations: Experience from an Italian Centre. Amyloid 25, 242\u2013246. https:\/\/doi.org\/10.1080\/13506129.2018.1545640 (2018).","journal-title":"Amyloid"},{"key":"69123_CR16","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore, J. D. et al. A new staging system for cardiac transthyretin amyloidosis. Eur. Heart J. 39, 2799\u20132806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589 (2018).","journal-title":"Eur. Heart J."},{"key":"69123_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/10408363.2019.1615034","volume":"56","author":"S Desmedt","year":"2019","unstructured":"Desmedt, S. et al. Growth differentiation factor 15: A novel biomarker with high clinical potential. Crit. Rev. Clin. Lab. Sci. 56, 333\u2013350. https:\/\/doi.org\/10.1080\/10408363.2019.1615034 (2019).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"69123_CR18","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1161\/01.RES.0000202805.73038.48","volume":"98","author":"T Kempf","year":"2006","unstructured":"Kempf, T. et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia\/reperfusion injury. Circ. Res. 98, 351\u2013360. https:\/\/doi.org\/10.1161\/01.RES.0000202805.73038.48 (2006).","journal-title":"Circ. Res."},{"key":"69123_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1152\/physiolgenomics.00168.2006","volume":"29","author":"A Clerk","year":"2007","unstructured":"Clerk, A., Kemp, T. J., Zoumpoulidou, G. & Sugden, P. H. Cardiac myocyte gene expression profiling during H2O2-induced apoptosis. Physiol. Genomics 29, 118\u2013127. https:\/\/doi.org\/10.1152\/physiolgenomics.00168.2006 (2007).","journal-title":"Physiol. Genomics"},{"key":"69123_CR20","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/HYPERTENSIONAHA.107.098046","volume":"51","author":"D Frank","year":"2008","unstructured":"Frank, D. et al. Gene expression pattern in biomechanically stretched cardiomyocytes: Evidence for a stretch-specific gene program. Hypertension 51, 309\u2013318. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.098046 (2008).","journal-title":"Hypertension"},{"key":"69123_CR21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1373\/clinchem.2012.182816","volume":"58","author":"C Widera","year":"2012","unstructured":"Widera, C. et al. Identification of follistatin-like 1 by expression cloning as an activator of the growth differentiation factor 15 gene and a prognostic biomarker in acute coronary syndrome. Clin. Chem. 58, 1233\u20131241. https:\/\/doi.org\/10.1373\/clinchem.2012.182816 (2012).","journal-title":"Clin. Chem."},{"key":"69123_CR22","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3109\/1354750X.2010.510580","volume":"15","author":"F Wang","year":"2010","unstructured":"Wang, F. et al. Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers 15, 671\u2013676. https:\/\/doi.org\/10.3109\/1354750X.2010.510580 (2010).","journal-title":"Biomarkers"},{"key":"69123_CR23","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.jacc.2007.04.091","volume":"50","author":"T Kempf","year":"2007","unstructured":"Kempf, T. et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J. Am. Coll. Cardiol. 50, 1054\u20131060. https:\/\/doi.org\/10.1016\/j.jacc.2007.04.091 (2007).","journal-title":"J. Am. Coll. Cardiol."},{"key":"69123_CR24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1161\/CIRCGENETICS.108.824870","volume":"2","author":"T Kempf","year":"2009","unstructured":"Kempf, T. et al. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: Results from the AtheroGene study. Circ. Cardiovasc. Genet. 2, 286\u2013292. https:\/\/doi.org\/10.1161\/CIRCGENETICS.108.824870 (2009).","journal-title":"Circ. Cardiovasc. Genet."},{"key":"69123_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3109\/00365513.2011.626072","volume":"72","author":"KM Eggers","year":"2012","unstructured":"Eggers, K. M. et al. Relations of growth-differentiation factor-15 to biomarkers reflecting vascular pathologies in a population-based sample of elderly subjects. Scand. J. Clin. Lab. Investig. 72, 45\u201351. https:\/\/doi.org\/10.3109\/00365513.2011.626072 (2012).","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"69123_CR26","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.amjcard.2013.05.013","volume":"112","author":"DJ Lok","year":"2013","unstructured":"Lok, D. J. et al. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure. Am. J. Cardiol. 112, 831\u2013837. https:\/\/doi.org\/10.1016\/j.amjcard.2013.05.013 (2013).","journal-title":"Am. J. Cardiol."},{"key":"69123_CR27","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1182\/blood-2017-12-819904","volume":"131","author":"E Kastritis","year":"2018","unstructured":"Kastritis, E. et al. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. Blood 131, 1568\u20131575. https:\/\/doi.org\/10.1182\/blood-2017-12-819904 (2018).","journal-title":"Blood"},{"key":"69123_CR28","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ehf2.13176","volume":"8","author":"M Okada","year":"2021","unstructured":"Okada, M. et al. Plasma growth differentiation factor 15: A novel tool to detect early changes of hereditary transthyretin amyloidosis. ESC Heart Fail. 8, 1178\u20131185. https:\/\/doi.org\/10.1002\/ehf2.13176 (2021).","journal-title":"ESC Heart Fail."},{"key":"69123_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2018.07.018","volume":"28","author":"VWW Tsai","year":"2018","unstructured":"Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1\/GDF15-GFRAL pathway in energy homeostasis: Implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353\u2013368. https:\/\/doi.org\/10.1016\/j.cmet.2018.07.018 (2018).","journal-title":"Cell Metab."},{"key":"69123_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","volume":"29","author":"S Patel","year":"2019","unstructured":"Patel, S. et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 29, 707-718 e708. https:\/\/doi.org\/10.1016\/j.cmet.2018.12.016 (2019).","journal-title":"Cell Metab."},{"key":"69123_CR31","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.cmet.2016.01.019","volume":"23","author":"J Nikkanen","year":"2016","unstructured":"Nikkanen, J. et al. Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. Cell Metab. 23, 635\u2013648. https:\/\/doi.org\/10.1016\/j.cmet.2016.01.019 (2016).","journal-title":"Cell Metab."},{"key":"69123_CR32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/nrm.2017.66","volume":"19","author":"A Suomalainen","year":"2018","unstructured":"Suomalainen, A. & Battersby, B. J. Mitochondrial diseases: The contribution of organelle stress responses to pathology. Nat. Rev. Mol. Cell Biol. 19, 77\u201392. https:\/\/doi.org\/10.1038\/nrm.2017.66 (2018).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"69123_CR33","doi-asserted-by":"publisher","first-page":"e16951","DOI":"10.15252\/emmm.202216951","volume":"15","author":"N Southwell","year":"2023","unstructured":"Southwell, N. et al. A coordinated multiorgan metabolic response contributes to human mitochondrial myopathy. EMBO Mol. Med. 15, e16951. https:\/\/doi.org\/10.15252\/emmm.202216951 (2023).","journal-title":"EMBO Mol. Med."},{"key":"69123_CR34","doi-asserted-by":"publisher","first-page":"13180","DOI":"10.3390\/ijms232113180","volume":"23","author":"B De Paepe","year":"2022","unstructured":"De Paepe, B. The cytokine growth differentiation factor-15 and skeletal muscle health: Portrait of an emerging widely applicable disease biomarker. Int. J. Mol. Sci. 23, 13180. https:\/\/doi.org\/10.3390\/ijms232113180 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"69123_CR35","doi-asserted-by":"publisher","first-page":"7576","DOI":"10.1523\/JNEUROSCI.21-19-07576.2001","volume":"21","author":"MM Sousa","year":"2001","unstructured":"Sousa, M. M. et al. Familial amyloid polyneuropathy: Receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J. Neurosci. 21, 7576\u20137586. https:\/\/doi.org\/10.1523\/JNEUROSCI.21-19-07576.2001 (2001).","journal-title":"J. Neurosci."},{"key":"69123_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neuro.2013.08.013","volume":"39","author":"VH Fong","year":"2013","unstructured":"Fong, V. H. & Vieira, A. Pro-oxidative effects of aggregated transthyretin in human Schwannoma cells. Neurotoxicology 39, 109\u2013113. https:\/\/doi.org\/10.1016\/j.neuro.2013.08.013 (2013).","journal-title":"Neurotoxicology"},{"key":"69123_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13506129.2018.1506919","volume":"25","author":"M Luigetti","year":"2018","unstructured":"Luigetti, M. et al. Progressive axonal polyneuropathy in a mitochondrial disorder: An uncommon association with familial amyloid neuropathy. Amyloid 25, 261\u2013262. https:\/\/doi.org\/10.1080\/13506129.2018.1506919 (2018).","journal-title":"Amyloid"},{"key":"69123_CR38","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nrneph.2017.101","volume":"13","author":"O Devuyst","year":"2017","unstructured":"Devuyst, O., Olinger, E. & Rampoldi, L. Uromodulin: From physiology to rare and complex kidney disorders. Nat. Rev. Nephrol. 13, 525\u2013544. https:\/\/doi.org\/10.1038\/nrneph.2017.101 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"69123_CR39","first-page":"597","volume":"132","author":"KL Sikri","year":"1981","unstructured":"Sikri, K. L., Foster, C. L., MacHugh, N. & Marshall, R. D. Localization of Tamm-Horsfall glycoprotein in the human kidney using immuno-fluorescence and immuno-electron microscopical techniques. J. Anat. 132, 597\u2013605 (1981).","journal-title":"J. Anat."},{"key":"69123_CR40","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1053\/j.ajkd.2021.03.026","volume":"78","author":"JH Ix","year":"2021","unstructured":"Ix, J. H. & Shlipak, M. G. The promise of tubule biomarkers in kidney disease: a review. Am. J. Kidney Dis. 78, 719\u2013727. https:\/\/doi.org\/10.1053\/j.ajkd.2021.03.026 (2021).","journal-title":"Am. J. Kidney Dis."},{"key":"69123_CR41","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2013010019","volume":"24","author":"CM O'Seaghdha","year":"2013","unstructured":"O\u2019Seaghdha, C. M. et al. Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes. J. Am. Soc. Nephrol. 24, 1880\u20131888. https:\/\/doi.org\/10.1681\/ASN.2013010019 (2013).","journal-title":"J. Am. Soc. Nephrol."},{"key":"69123_CR42","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.04230415","volume":"11","author":"M Pruijm","year":"2016","unstructured":"Pruijm, M. et al. Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general population. Clin. J. Am. Soc. Nephrol. 11, 70\u201380. https:\/\/doi.org\/10.2215\/CJN.04230415 (2016).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"69123_CR43","first-page":"5","volume":"15","author":"AB Dawnay","year":"1981","unstructured":"Dawnay, A. B. & Cattell, W. R. Serum Tamm-Horsfall glycoprotein levels in health and in renal disease. Clin. Nephrol. 15, 5\u20138 (1981).","journal-title":"Clin. Nephrol."},{"key":"69123_CR44","doi-asserted-by":"publisher","first-page":"995","DOI":"10.20452\/pamw.3712","volume":"126","author":"D Fedak","year":"2016","unstructured":"Fedak, D. et al. Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol. Arch. Med. Wewn. 126, 995\u20131004. https:\/\/doi.org\/10.20452\/pamw.3712 (2016).","journal-title":"Pol. Arch. Med. Wewn."},{"key":"69123_CR45","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1515\/cclm-2014-0505","volume":"52","author":"L Risch","year":"2014","unstructured":"Risch, L. et al. The serum uromodulin level is associated with kidney function. Clin. Chem. Lab. Med. 52, 1755\u20131761. https:\/\/doi.org\/10.1515\/cclm-2014-0505 (2014).","journal-title":"Clin. Chem. Lab. Med."},{"key":"69123_CR46","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/medicina58121729","volume":"58","author":"M Vukmirovi\u0107 Papuga","year":"2022","unstructured":"Vukmirovi\u0107 Papuga, M. et al. Serum uromodulin, a potential biomarker of tubulointerstitial damage, correlates well with measured GFR and ERPF in patients with obstructive nephropathy. Medicina (Kaunas) 58, 1729. https:\/\/doi.org\/10.3390\/medicina58121729 (2022).","journal-title":"Medicina (Kaunas)"},{"key":"69123_CR47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/ckj\/sfac156","volume":"16","author":"V D'Ambrosio","year":"2023","unstructured":"D\u2019Ambrosio, V., Ferraro, P. M., Guglielmino, V. & Luigetti, M. Kidney involvement in hereditary transthyretin amyloidosis: Is there a role for cystatin C?. Clin. Kidney J. 16, 397\u2013398. https:\/\/doi.org\/10.1093\/ckj\/sfac156 (2023).","journal-title":"Clin. Kidney J."},{"key":"69123_CR48","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.3390\/genes13122236","volume":"13","author":"M Luigetti","year":"2022","unstructured":"Luigetti, M. et al. Trajectories of kidney function in patients with ATTRv treated with gene silencers. Genes (Basel) 13, 2236. https:\/\/doi.org\/10.3390\/genes13122236 (2022).","journal-title":"Genes (Basel)"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69123-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69123-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T04:07:24Z","timestamp":1723003644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-69123-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["69123"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-69123-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M. Luigetti received financial grants (honoraria and speaking) from Ackea, Alnylam, Sobi, and Pfizer and travel grants from Ackea, Alnylam, Sobi, Pfizer, Kedrion, and Grifols. A. Romano received financial grants (honoraria and speaking) from Akcea and travel grants from Akcea, Alnylam, Pfizer, and Csl Behring. P. M. Ferraro received grants\/consultant fees from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, BioHealth Italia, Gilead, Otsuka Pharmaceuticals, and Vifor Fresenius. Guido Primiano received financial grants (honoraria and speaking) from Sanofi. The other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18281"}}